Since the 1990s, Woxford has applied our high-performance anaerobic bioreactor technology to challenging wastewater treatment projects in the pharmaceutical industry. After improvements and enhancements to our GX/HP-advanced anaerobic bioreactor technology spanning 20 years, it now offers not only complete treatment solutions for highly concentrated organic wastewater in large daily production volumes, but also advanced features in enhanced degradation of recalcitrant organic pollutants, and greater buffer capability to inhibitory and toxic compounds, such as antibiotics.
See below for more details of key projects employing Woxford's biological wastewater treatment systems.
Key Clients and Projects
The world's largest antibiotic manufacturer: NCPC
North China Pharmaceutical Group Corp. AKA NCPC
A key national project of China's First Five-Year Plan, aided by the Soviet Union
The largest pharmaceutical company in China
The world's largest manufacturer of antibiotics
The world's largest manufacturer of pharmaceutical intermediates.
In 1995, four full-scale I-GX/HP-Anaerobic Bioreactors (1st-Gen) were installed at NCPC for the disposal of pharmaceutical wastewater.
Flow rate: 2,000 m /day
Influent COD: 10,000mg/L
Over 90% Removed
Since 1999, Woxford's advanced anaerobic bioreactor technology has been employed in the disposal of antibiotic wastewater and at the core of complete and cost-effective solutions. To date, it has been widely employed in the disposal of effluents produced in the manufacturing of avermectin/abamectin, gentamicin, neomycin sulphate and drug intermediates.